Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00012064 | Vaccine Therapy in Treating Patients With Stage IV or Recurrent Melanoma | PHASE1 | COMPLETED | 56 | — | — | Jul 1, 2000 | Apr 1, 2011 | Jan 29, 2014 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| Biological/Vaccine | EXPERIMENTAL | Biological/Vaccine: therapeutic autologous dendritic cells. Apheresis procedure collects peripheral blood mononuclear cells (PBMC) for the production of dendritic cell, which are admixed with irradiated tumor cells from autologous tumor cell line for vaccine product. |
| Name | Type | Description |
|---|---|---|
| therapeutic autologous dendritic cells | BIOLOGICAL | Apheresis procedure collects peripheral blood mononuclear cells (PBMC) for the production of dendritic cell, which are admixed with irradiated tumor cells from autologous tumor cell line for vaccine product. |
DISEASE CHARACTERISTICS: * Histologically confirmed stage IV or recurrent melanoma * Metastatic disease confirmed by MRI or CT scan * Planned resection of tumor * No active CNS metastases * Radiographically confirmed lack of CNS disease progression * No requirement for pharmacologic doses o...